Role of Hormonal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence after Local Curative Treatment: A Systematic Review

European Urology

Volumn 69, Issue 5, 2016, Pages 802-820

  Van Den Bergh, Roderick C N ^a   Van Casteren, Niels J ^b   Van Den Broeck, Thomas ^c   Fordyce, Eve R ^d   Gietzmann, William K M ^e   Stewart, Fiona ^d   MacLennan, Steven ^d   Dabestani, Saeed ^f   Bellmunt, Joaquim ^g   Bolla, Michel ^h   Briers, Erik ⁱ   Cornford, Philip ^j   Joniau, Steven ^c   Mason, Malcolm D ^k   Matveev, Vsevolod ^l   Van Der Poel, Henk G ^m   Van Der Kwast, Theo H ⁿ   Rouvière, Olivier ^o   Wiegel, Thomas ^p   Lam, Thomas B ^d,e   Mottet, Nicolas ^q   more..

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b IJSSELLAND HOSPITAL   (Netherlands)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d UNIVERSITY OF ABERDEEN   (United Kingdom)

^e ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^f LUND UNIVERSITY HOSPITAL   (Sweden)

^g HARVARD MEDICAL SCHOOL   (United States)

^h HÔPITAL MICHALLON   (France)

ⁱ Hasselt ^*  (Belgium)

^j ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^k VELINDRE CANCER CENTRE   (United Kingdom)

^l N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^m NETHERLANDS CANCER INSTITUTE   (Netherlands)

ⁿ ERASMUS MEDICAL CENTER   (Netherlands)

^o EDOUARD HERRIOT HOSPITAL   (France)

^p UNIVERSITY HOSPITAL ULM   (Germany)

^q UNIVERSITÉ JEAN MONNET   (France)

more..

Author keywords

Curative treatment; EAU; Guidelines; Hormonal; Non metastatic; Prostate cancer; Recurrence; Systematic review; Therapy

Indexed keywords

ANTIANDROGEN; GONADORELIN; GONADORELIN ANTAGONIST; PROSTATE SPECIFIC ANTIGEN; ESTROGEN;

BRACHYTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER THERAPY; CLINICAL EFFECTIVENESS; COMORBIDITY; COMPARATIVE STUDY; CRYOTHERAPY; FOLLOW UP; GLEASON SCORE; HEALTH CARE QUALITY; HORMONAL THERAPY; HUMAN; LIFE EXPECTANCY; LOCAL THERAPY; MALE; METASTASIS FREE SURVIVAL; MONOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; SEMINAL VESICLE; SYSTEMATIC REVIEW; SYSTEMIC THERAPY; TREATMENT OUTCOME; AGONISTS; ANTAGONISTS AND INHIBITORS; BLOOD; ORCHIECTOMY; PATHOLOGY; PROCEDURES; PROSTATE TUMOR; SALVAGE THERAPY; TIME FACTOR; TUMOR RECURRENCE;

ANDROGEN ANTAGONISTS; ESTROGENS; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ORCHIECTOMY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SALVAGE THERAPY; TIME FACTORS;

EID: 84949654377     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2015.11.023     Document Type: Review

References (46)

1. Mottet N, Bastian PJ, Briers E, et al. Guidelines on prostate cancer. Presented at: European Association of Urology annual congress; March 20-24, 2015; Madrid, Spain.
2. M. Roach 3rd., G. Hanks, H. Thames Jr., P. Schellhammer, W.U. Shipley, G.H. Sokol, and H. Sandler Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference Int J Radiat Oncol Biol Phys 65 4 2006 965 974
3. A.J. Stephenson, M.W. Kattan, J.A. Eastham, and et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition J Clin Oncol 24 2006 3973 3978
4. J. Sylvester, J. Blasko, P. Grimm, R. Meier, J. Spiegel, and J. Malmgren Fifteen year follow up of the first cohort of localized prostate cancer patients treated with brachytherapy [abstract 4567] J Clin Oncol 22 Suppl 2004
5. C.R. Pound, A.W. Partin, M.A. Eisenberger, D.W. Chan, J.D. Pearson, and P.C. Walsh Natural history of progression after PSA elevation following radical prostatectomy JAMA 281 1999 1591 1597
6. A.V. D'Amico, J.W. Denham, J. Crook, and et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions J Clin Oncol 25 2007 2420 2425
7. J.P. Higgins, D.G. Altman, P.C. Gotzsche, and et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials BMJ 343 2011 d5928
8. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions v.5.0.2. Cochrane Collaboration Web site. http://community.cochrane.org/handbook
9. J.J. Deeks, J. Dinnes, R. D'Amico, and et al. Evaluating non-randomised intervention studies Health Technol Assess 7 2013 1 173
10. Reeves BC, Deeks JJ, Higgins J, Wells GA. Cochrane Non-Randomized Studies Methods Group. Including non-randomised studies. In: Higgins J, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0. Cochrane Collaboration Web site. http://www.cochrane-handbook.org. Updated March 2011.
11. K. Dalziel, A. Round, K. Stein, R. Garside, E. Castelnuovo, and L. Payne Do the findings of case series studies vary significantly according to methodological characteristics? Health Technol Assess 9 2005 1 146
12. Viswanathan M, Ansari M, Berkman N, et al. Methods guide for comparative effectiveness reviews. Assessing the risk of bias of individual studies in systematic reviews of health care interventions. Agency for Healthcare Research and Quality Web site. http://www.effectivehealthcare.ahrq.gov/ehc/products/322/998/MethodsGuideforCERs-Viswanathan-IndividualStudies.pdf
13. Popay J, Roberts H, Sowden A, et al. Guidance on the conduct of narrative synthesis in systematic reviews: a product from the ESRC Methods Programme. Lancaster University Institute for Health Research Web site. http://www.lancaster.ac.uk/shm/research/nssr/research/dissemination/publications/NS-Synthesis-Guidance-v1.pdf
14. J.M. Crook, C.J. O'Callaghan, G. Duncan, and et al. Intermittent androgen suppression for rising PSA level after radiotherapy N Engl J Med 367 2012 895 903
15. G. Duchesne, J. Bassett, C. D'Este, and et al. The "Timing of androgen deprivation therapy in prostate cancer patients with a rising PSA (TOAD)" collaborative randomised phase III trial [abstract 5007] J Clin Oncol 33 Suppl 2015
16. X. Garcia-Albeniz, J.M. Chan, A. Paciorek, and et al. Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study Eur J Cancer 51 2015 817 824
17. L.L. Kestin, F.A. Vicini, and A.A. Martinez Potential survival advantage with early androgen deprivation for biochemical failure after external beam radiotherapy: the importance of accurately defining biochemical disease status Int J Radiat Oncol Biol Phys 60 2004 453 462
18. T. Klayton, K. Ruth, M. Buyyounouski, and et al. PSA doubling time predicts for the development of distant metastases for patients who fail 3DCRT OR IMRT using the Phoenix definition Pract Radiat Oncol 1 2011 235 242
19. J.W. Moul, H. Wu, L. Sun, and et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy J Urol 171 2008 1141 1147
20. W.H. Pinover, E.M. Horwitz, A.L. Hanlon, R.G. Uzzo, and G.E. Hanks Validation of a treatment policy for patients with prostate specific antigen failure after three-dimensional conformal prostate radiation therapy Cancer 97 2003 1127 1133
21. S.A. Siddiqui, S.A. Boorjian, B. Inman, S. Bagniewski, E.J. Bergstralh, and M.L. Blute Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study J Urol 179 2008 1830 1837
22. S. Taguchi, H. Fukuhara, T. Azuma, and et al. Ultra-early versus early salvage androgen deprivation therapy for post-prostatectomy biochemical recurrence in pT2-4N0M0 prostate cancer BMC Urol 14 2014 81
23. M.B. Kim, M.H. Chen, M. de Castro, M. Loffredo, P.W. Kantoff, and A.V. D'Amico Defining the optimal approach to the patient with postradiation prostate-specific antigen recurrence using outcome data from a prospective randomized trial Cancer 119 2013 3280 3286
24. R. Algarra, M. Hevia, A. Tienza, and et al. Survival analysis of patients with biochemical relapse after radical prostatectomy treated with androgen deprivation: castration-resistance influential factors Can Urol Assoc J 8 2014 E333 E341
25. V. Bertaglia, M. Tucci, C. Fiori, and et al. Effects of serum testosterone levels after 6 months of androgen deprivation therapy on the outcome of patients with prostate cancer Clin Genitourin Cancer 11 2013 325-30.e1
26. T.K. Choueiri, M.H. Chen, A.V. D'Amico, and et al. Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death Cancer 116 2010 1887 1892
27. A. de la Taille, M. Zerbib, S. Conquy, D. Amsellem-Ouazana, D. Saighi, and B. Debre Study of intermittent endocrine therapy in patients presenting with biologic recurrence after radical prostatectomy or radiotherapy [in French] Prog Urol 12 2002 240 247
28. D. Keizman, P. Huang, E.S. Antonarakis, and et al. The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen deprivation Prostate 71 2011 1608 1615
29. C. Kim-Sing, and T. Pickles Prostate Cohort Outcomes I. Intervention after PSA failure: examination of intervention time and subsequent outcomes from a prospective patient database Int J Radiat Oncol Biol Phys 60 2004 463 469
30. N.E. Martin, M.H. Chen, C.J. Beard, and et al. Natural history of untreated prostate specific antigen radiorecurrent prostate cancer in men with favorable prognostic indicators Prostate Cancer 2014 2014 912943
31. J.P. Monk, S. Halabi, J. Picus, and et al. Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782 Cancer 118 2012 4139 4147
32. D.M. Moreira, M.R. Cooperberg, L.E. Howard, and et al. Predicting bone scan positivity after biochemical recurrence following radical prostatectomy in both hormone-naive men and patients receiving androgen-deprivation therapy: results from the SEARCH database Prostate Cancer Prostatic Dis 17 2014 91 96
33. M.V. Pilepich, K. Winter, C.A. Lawton, and et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31 Int J Radiat Oncol Biol Phys 61 2005 1285 1290
34. C.R. Porter, A. Gallina, K. Kodama, and et al. Prostate cancer-specific survival in men treated with hormonal therapy after failure of radical prostatectomy Eur Urol 52 2007 446 452
35. N.A. Rodrigues, M.H. Chen, W.J. Catalona, K.A. Roehl, J.P. Richie, and A.V. D'Amico Predictors of mortality after androgen-deprivation therapy in patients with rapidly rising prostate-specific antigen levels after local therapy for prostate cancer Cancer 107 2006 514 520
36. P. Rodrigues, F.O. Hering, and A. Meller Adjuvant effect of IV clodronate on the delay of bone metastasis in high-risk prostate cancer patients: a prospective study Cancer Res Treat 43 2011 231 235
37. A. Sciarra, S. Cattarino, A. Gentilucci, and et al. Predictors for response to intermittent androgen deprivation (IAD) in prostate cancer cases with biochemical progression after surgery Urol Oncol 31 2013 607 614
38. W.U. Shipley, M. Desilvio, M.V. Pilepich, and et al. Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: a secondary analysis of RTOG protocol 86-10 Int J Radiat Oncol Biol Phys 64 2006 1162 1167
39. D.E. Spratt, Z.S. Zumsteg, X. Pei, and et al. Predictors of castration-resistant prostate cancer after dose-escalated external beam radiotherapy Prostate 75 2015 175 182
40. E.Y. Yu, K.F. Kuo, R. Gulati, and et al. Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer J Clin Oncol 30 2012 1864 1870
41. S.A. Boorjian, R.H. Thompson, M.K. Tollefson, and et al. Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence Eur Urol 59 2011 893 899
42. F. Kunath, H.R. Grobe, G. Rucker, and et al. Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer Cochrane Database Syst Rev 2014 CD009266
43. B.J. Trock, M. Han, S.J. Freedland, and et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy JAMA 299 2008 2760 2769
44. Z.S. Zumsteg, D.E. Spratt, P.B. Romesser, and et al. The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy Eur Urol 67 2015 1009 1016
45. G.N. Levine, A.V. D'Amico, P. Berger, and et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology Circulation 121 2010 833 840
46. S. O'Farrell, H. Garmo, L. Holmberg, J. Adolfsson, P. Stattin, and M. Van Hemelrijck Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer J Clin Oncol 33 2015 1243 1251